Systemic mastocytosis

Haematology
#ASH 2025 #Sanofi #Systemic mastocytosis

Ayvakit is safe long-term treatment for systemic mastocytosis 

New results show Ayvakit (avapritinib) is an effective and safe long-term treatment for systemic mastocytosis (SM).  The data, announced by Sanofi company Blueprint Medicines, showed Ayvakit led to sustained symptom and quality-of-life benefits in indolent SM (ISM) after a median follow-up of more than three years, and extended survival rates in… Read More

#News

#Alys Pharmaceuticals #Atopic dermatitis #Biotechnology #Cold Urticaria #Dermatology #Drug discovery #Mastocytosis #Seed funding #Systemic mastocytosis

New podcast: First-in-class mechanisms for the next wave of dermatology innovation

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Thibaud Portal, Founder… Read More

#News